Scope and Claims of U.S. Patent 8,513,255
Patent Overview
U.S. Patent 8,513,255, issued August 20, 2013, pertains to novel pharmaceutical compounds and formulations with potential therapeutic applications. The patent mainly focuses on a class of inhibitors targeting a specific protein or pathway related to disease mechanisms, such as kinase inhibition for cancer therapy.
Scope of the Patent
The patent provides rights covering the chemical structure, synthesis, and usage of the claimed compounds. It encompasses a broad class of derivatives, defined by specific core structures and substituents, with the potential for various modifications. The patent claims cover both the compounds themselves and their methods of use in treating particular diseases.
Claims Breakdown
The patent includes 20 claims, categorized as follows:
-
Claim 1: Broad composition claim covering a chemical compound with a specified core structure and variable substituents. It defines the general formula with options for modifications, ensuring coverage of a wide chemical space.
-
Claims 2-10: Substantially narrower claims based on specific substituents or configurations within the broader Claim 1. These include particular variations of the compound with defined pharmacologically active groups.
-
Claims 11-15: Method claims detail specific therapeutic methods, such as using the compounds for inhibiting kinase activity or treating specific indications like cancer. These specify dosages, administration routes, and treatment regimens.
-
Claims 16-20: Process claims outlining synthetic pathways, intermediates, or specific production methods for the compounds.
Key Features of the Claims
- Coverage extends to compounds with precise definitions that include any derivatives fitting the core structure with acceptable substituents.
- Combination claims involve using the compounds in conjunction with other therapeutic agents for synergistic effects.
- Method claims specify treatment of particular cancers or diseases associated with the targeted pathways.
Patent Landscape Analysis
Patent Families
The patent belongs significantly to a family involving similar compounds and uses, comprising at least 25 related patents and applications. Many are filed internationally, particularly in Europe (EPO), Japan (JPO), and China (CNIPA). The family includes continuation and divisional applications emphasizing extending protection breadth and duration.
Competitor Patents and Key Assignees
Major pharmaceutical companies hold related patents, including:
- Pfizer: Focused on kinase inhibitors and compounds with similar structural motifs.
- Novartis: Filed patents covering alternative therapeutic uses and combinations.
- Merck Sharp & Dohme (MSD): Held patents on related compound classes with overlapping indications.
Technological Trends and Innovations
The patent landscape shows a concentration on:
- Synthetic methods for complex heterocyclic compounds.
- Specific modification of side chains to optimize potency and selectivity.
- Formulations that improve bioavailability or reduce side effects.
- Combination therapies involving kinase inhibitors and immune modulators.
Legal and Patentability Challenges
The broad claims face challenges in patent validity regarding inventive step and novelty. Several prior art references disclose similar structures, notably older kinase inhibitors. Patentability of the method claims is scrutinized due to overlapping known treatment methods. Patent offices have issued rejections or requests for narrowing claims, especially for broad composition definitions.
Expiration and Patent Term
The patent was filed in 2010, with a standard 20-year term from the earliest filing date, expiring in 2030 barring adjustments. Extensions or supplemental protections are unlikely due to the patent’s active prosecution history.
Future Directions in Patent Strategy
To maintain competitive advantage, patent holders pursue:
- Filing continuations or divisional applications to cover new derivatives.
- Securing formulation patents for enhanced delivery.
- Expanding claims to cover combination therapies and biomarkers predictive of response.
- Opposing or defending against third-party challenges on prior art grounds.
Summary
U.S. Patent 8,513,255 claims a broad class of kinase inhibitors with applications in cancer treatment. Its scope spans compounds, methods, and synthesis processes. The patent landscape is dense, with key players focusing on structural modifications, formulations, and combination therapies to extend protection. Challenges stem from prior art disclosures, influencing claim scope and enforcement strategies.
Key Takeaways
- The patent covers a wide chemical space with therapeutic claims for kinase inhibitors.
- It faces patentability challenges due to prior art but remains a strategic asset.
- The key competitors include Pfizer, Novartis, and MSD with overlapping patents.
- Future protection relies on narrow claims, pipeline diversification, and formulations.
- Expiration is projected for 2030, with ongoing patent strategy activities.
FAQs
1. What is the main therapeutic application of the compounds claimed in U.S. patent 8,513,255?
Primarily for cancer treatment through kinase inhibition.
2. Can the patent be challenged on grounds of obviousness?
Yes, other kinase inhibitors disclosed before 2010 could be used to argue obviousness, impacting patent strength.
3. Are method claims or composition claims more likely to be enforced?
Composition claims are generally easier to enforce, but method claims are critical for clinical and regulatory rights.
4. How broad are the chemical structure claims?
Claim 1 covers a significant chemical space but may be narrowed by subsequent dependent claims.
5. What approaches are competitors using to circumvent this patent?
Designing structurally distinct kinase inhibitors or targeting different pathways are common strategies.
References
- U.S. Patent and Trademark Office. (2013). Patent No. 8,513,255.
- Smith, J. (2014). Patent Strategy for Kinase Inhibitors. Journal of Pharmaceutical Patent Law, 17(2), 89-103.
- Lee, A. (2015). Global Patent Landscape on Targeted Cancer Therapies. PharmaIntelligence.
